Syndax Pharmaceuticals (SNDX) Accounts Payables (2015 - 2026)

Syndax Pharmaceuticals' Accounts Payables history runs 12 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 7.92% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 7.92% YoY), while the FY2025 annual figure was $16.6 million, up 42.61% from the prior year.
• Accounts Payables for Q1 2026 stood at $10.8 million, down from $16.6 million in the prior quarter.
• The five-year high for Accounts Payables was $17.4 million in Q2 2025, with the low at $4.4 million in Q4 2022.
• The 5-year median for Accounts Payables is $10.0 million (2023), against an average of $9.8 million.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables fell 23.27% in 2022, then surged 182.28% in 2025.
• Syndax Pharmaceuticals' Accounts Payables stood at $4.4 million in 2022, then surged by 128.99% to $10.0 million in 2023, then grew by 16.72% to $11.6 million in 2024, then jumped by 42.61% to $16.6 million in 2025, then sank by 34.6% to $10.8 million in 2026.
• Business Quant data shows SNDX's Accounts Payables at $10.8 million in Q1 2026, $16.6 million in Q4 2025, and $13.8 million in Q3 2025.